Loading
IARC estimates 24,836 new cancer cases and 14,495 cancer deaths in Yemen in 2024; the commonest new cancers are breast, trachea, bronchus and lung and leukaemia. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Yemen's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 5,299 | 42.7 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Trachea, bronchus and lung | 1,870 | 11.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 1,823 | 6.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Colorectum | 1,509 | 7.3 | Colorectal cancer |
| Brain, central nervous system | 1,254 | 4.5 | Glioma & glioblastoma |
| Bladder | 1,216 | 7.1 | Bladder & urothelial cancer |
| Non-Hodgkin lymphoma | 1,213 | 4.9 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Thyroid | 1,117 | 3.7 | Thyroid cancer |
| Stomach | 755 | 3.8 | Gastric & gastro-oesophageal junction cancer |
| Hodgkin lymphoma | 694 | 2.0 | Hodgkin lymphoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Breast | 2,335 | 19.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Trachea, bronchus and lung | 1,765 | 10.5 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 1,158 | 4.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Brain, central nervous system | 987 | 3.8 | Glioma & glioblastoma |
| Colorectum | 834 | 4.4 | Colorectal cancer |
| Bladder | 720 | 4.4 | Bladder & urothelial cancer |
| Stomach | 580 | 3.2 | Gastric & gastro-oesophageal junction cancer |
| Non-Hodgkin lymphoma | 532 | 2.4 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Pancreas | 528 | 3.0 | Pancreatic ductal adenocarcinoma |
| Liver and intrahepatic bile ducts | 466 | 2.6 | Hepatocellular carcinoma |
No trial record in OnCo lists a site in Yemen. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Yemen.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Yemen is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Yemen is ranked 47 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.